Supply High Quality Pharmaceutical Grade Dienogest CAS 65928-58-7

• Powder: Yes
• Customized: Non-Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Model NO.: Hmj-Dienogest
• Color: White
• Mf: C20h25no2
• Einecs: 639-448-2
• Molecular Weight: 311.43
• Test Method: HPLC
• CAS: 65928-58-7
• Shelf Life: 2 Years
• Grade: Pharmaceutical Grade
• Transport Package: Ziplock Foil Bag. Drum
• Specification: 1kg Per Foil Bag, 10 Bags Per Carton, 25 Kg Per Dr
• Trademark: HMJ
• Origin: China
• Production Capacity: 200kg/Month

Product Description

Supply High Quality Pharmaceutical Grade Dienogest CAS 65928-58-7 

Product Description

 

Product Name	Supply High Quality Pharmaceutical Grade Dienogest CAS 65928-58-7
Appearance	White powder
Molecular formula	C20H25NO2
Molecular weight	311.43
Keywords	Dienogest  , Material Dienogest  ; Pure Dienogest
Shelf Life	24 months when properly stored
Storage	Keep in a cool, dry, dark location

Function

 

What is Dienogest?

Dienogest(STS-557) is a specific progesterone receptor agonist with potent oral endometrial activity and is used in the treatment of endometriosis. Target: progesterone receptor agonistDienogest is an orally active synthetic progesterone (or progestin). It is available for use as an oral contraceptive in combination with ethinylestradiol.  Complete sperm suppression was observed in rats sacrificed either 60 or 90 days after dienogest (DNG) undecanoate (TU) administration, for two injections at 45-day interval. The neutral α-glucosidase activity in these treated rats remained in the normal range. Germ cell loss due to apoptosis was frequently observed both after 60 or 90 days of combination treatment. Significant decline in serum, both serum and intratesticular levels, were observed in the treated rats. Following stoppage of treatment (given at 45-day interval) after two (0 and 45 days) or three injections (0, 45 and 90 days), complete restoration of spermatogenesis was observed by 120 and 165 days, respectively [2].Clinical indications: Adenomyosis; EndometriosisFDA Approved Date: 1995 Toxicity: weight gain; increased blood pressure; breast tenderness and nausea.



Function of Dienogest

 

(1) Dienogest has moderate affinity for the progesterone receptor in human uterus tissue, in vitro, about 10% that of progesterone.
(2) Inhibition of ovulation

The minimum effective dose of oral dienogest required to inhibit ovulation is 1 mg/day. The inhibition of ovulation by dienogest occurs mainly via peripheral action as opposed to central action on gonadotrophin secretion. Oral treatment of dienogest 2 mg/day in cyclical women reduced serum progesterone levels to anovulatory levels, however serum levels of lutenising hormone and follicle-stimulating hormone are not significantly altered. 

 

Detailed Photos

 

 

 

Related Product

Packaging & Shipping